IKT
Inhibikase·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 1
Bearish signal 2
Ample Liquidity
Significant Net Income Decline
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About IKT
Inhibikase Therapeutics, Inc.
A clinical stage pharmaceutical company that develops therapeutics for Parkinson’s Disease and related brain disorders
Biological Technology
06/03/2010
12/23/2020
NASDAQ Stock Exchange
15
12-31
Common stock
1000 N. West Street, Suite 1200, Wilmington, DE 19801
--
Inhibikase Therapeutics, Inc., was incorporated as a Delaware corporation on June 3, 2010. The company is a clinical-stage pharmaceutical company developing therapies for Parkinson's disease or PD and related diseases that occur inside and outside the brain.
Company Financials
EPS
IKT has released its 2025 Q3 earnings. EPS was reported at -0.13, versus the expected -0.13, meeting expectations. The chart below visualizes how IKT has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
